Written Informed Consent Act
- Bill Number
- H.R. 4837
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2025-12-19: Referred to the Subcommittee on Health.
- Last Updated
- 2026-06-24T08:08:22Z
AI-Generated Summary
Purpose of the Legislation
The "Written Informed Consent Act" (H.R. 4837) aims to enhance patient safety and autonomy in Veterans Affairs (VA) healthcare by requiring written informed consent for a broader range of medications. Informed consent means patients must be fully informed about the risks, benefits, and alternatives of a treatment before agreeing to it. This bill expands an existing VA policy focused on opioids to include other commonly prescribed drugs.
Key Provisions
- Directive Update: The Secretary of Veterans Affairs must revise VHA Directive 1005 (issued May 13, 2020, and originally titled "Informed Consent for Long-term Opioid Therapy for Pain").
- Expanded Scope: The updated directive will require written informed consent for long-term use of the following medication types:
- Antipsychotics (drugs used to treat conditions like schizophrenia or bipolar disorder).
- Stimulants (medications often prescribed for attention deficit hyperactivity disorder or narcolepsy).
- Antidepressants (treatments for depression and related mental health issues).
- Anxiolytics (drugs to reduce anxiety, such as benzodiazepines).
- Narcotics (pain-relieving opioids, building on the original directive).
Significant Changes to Existing Law
- The original VHA Directive 1005 applies only to long-term opioid therapy for pain management.
- This bill extends the informed consent requirement to the additional medication categories listed above, mandating written documentation to ensure consistency and standardization in VA practices.
- No new penalties or enforcement mechanisms are introduced; the focus is on policy expansion within the VA system.
Potential Impacts
- On Government Agencies: The Department of Veterans Affairs (VA) and its Veterans Health Administration (VHA) will need to implement training, update forms, and integrate the new requirements into clinical workflows, potentially increasing administrative workload but improving compliance with patient rights standards.
- On Citizens: Veterans receiving these medications through VA healthcare will gain clearer information about treatment risks, empowering them to make more informed decisions. This could lead to fewer adverse effects from uninformed prescribing but might delay access to urgent care if consent processes slow down.
- On International Relations: No direct impacts, as the bill is limited to domestic VA operations.
Main Stakeholders Affected
- Veterans: Primary beneficiaries, as patients in the VA system who are prescribed these medications.
- VA Healthcare Providers: Doctors, nurses, and pharmacists who must obtain and document informed consent.
- VA Leadership: The Secretary of Veterans Affairs and VHA officials responsible for updating and enforcing the directive.
- Congressional Oversight: The House Committee on Veterans' Affairs, which reviews the bill.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens existing federal requirements under VA regulations for patient protections (e.g., aligning with broader healthcare laws like those emphasizing informed consent in medical ethics). It promotes accountability without creating new litigation risks, as it builds on an established directive.
- Constitutional: Supports First Amendment principles of informed decision-making and due process in healthcare, but raises no significant challenges to individual rights or federal authority.
- Political: Highlights bipartisan focus on veteran mental health and pain management (introduced by Rep. Bilirakis with co-sponsors from both parties). It could influence future VA funding debates by emphasizing preventive care measures, potentially appealing to constituents concerned with over-prescription issues in public health.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Bilirakis, Gus M. [R-FL-12]
Cosponsors (21)
Rep. Bergman, Jack [R-MI-1], Rep. Self, Keith [R-TX-3], Rep. Van Drew, Jefferson [R-NJ-2], Rep. Fields, Cleo [D-LA-6], Rep. Hill, J. French [R-AR-2], Rep. Massie, Thomas [R-KY-4], Rep. Barr, Andy [R-KY-6], Rep. Grothman, Glenn [R-WI-6], Rep. Fitzgerald, Scott [R-WI-5], Rep. Owens, Burgess [R-UT-4], Rep. Stauber, Pete [R-MN-8], Rep. Edwards, Chuck [R-NC-11], Del. Radewagen, Aumua Amata Coleman [R-AS-At Large], Rep. Guest, Michael [R-MS-3], Rep. Lawler, Michael [R-NY-17], Rep. Davis, Donald G. [D-NC-1], Rep. Harrigan, Pat [R-NC-10], Rep. Barrett, Tom [R-MI-7], Rep. Miller, Max L. [R-OH-7], Rep. Kennedy, Mike [R-UT-3], Rep. Ciscomani, Juan [R-AZ-6]
Recent Actions
- 2025-12-19: Referred to the Subcommittee on Health.
- 2025-08-01: Referred to the House Committee on Veterans' Affairs.
- 2025-08-01: Introduced in House
- 2025-08-01: Introduced in House
Bill Versions
- Written Informed Consent Act — issued 2025-08-01 — PDF (2 pages)